Reviewing Vireo Growth (VREOD) and Its Rivals

Vireo Growth (OTCMKTS:VREOD) is one of 903 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Vireo Growth to related companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, profitability, dividends and risk.

Volatility & Risk

Vireo Growth has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s rivals have a beta of -3.18, meaning that their average stock price is 418% less volatile than the S&P 500.

Valuation and Earnings

This table compares Vireo Growth and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$3.47 billion	$3.12 billion	547.15

Vireo Growth’s rivals have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Vireo Growth shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Vireo Growth and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,299.79%	-222.94%	-17.42%

Analyst Ratings

This is a summary of current ratings and recommmendations for Vireo Growth and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7588	13648	25437	997	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 30.94%. Given Vireo Growth’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its rivals.

Summary

Vireo Growth rivals beat Vireo Growth on 9 of the 13 factors compared.

About Vireo Growth

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.